Creatine

• Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments
  As part of their cooperation, Alzchem Group AG and Crearene AG announced in October 2023 that a clinical study on the use of creatine in dialysis treatments had been launched.
• The aim is to demonstrate the technical feasibility, patient safety and dose finding of creatine-based dialysis treatment solutions.
• Using specially purified creatine from the Alzchem Group, a University Medical Center Groningen team, led by Prof. Dr. Stephan J.L.
• Based on the promising initial results, Alzchem Group AG and Crearene AG have extended their collaboration to develop creatine-based treatment solutions for medical applications until the end of 2025.

• Bizz Energy was designed as an antidote to the typical energy drink concept.
• The Bizz Energy formula is also packed with nutritional ingredients that help with more than just energy — they support strength and muscle mass, too.
• We use natural ingredients, like essential amino acids and creatine, to enhance strength and improve muscle mass over the long-term, too.
• This circumvents the infamous concept of a sugary, short-term energy drink, establishing Bizz Energy as a health and wellness tool that enhances nutrition, builds muscle mass, and delivers clean, crash-free energy whenever it is most needed.

• The marketing of dietary supplements has been quite effective, with 77% of Americans reporting feeling that the supplement industry is trustworthy.
• A 2024 study found that approximately 1 in 10 adolescents have used nonprescribed weight loss and weight control products, including dietary supplements.
• The unregulated market of dietary supplements is setting consumers up to be misled and potentially seriously harmed by these products.

The wild west

• Some of these products are labeled as dietary supplements but are anything but.
• Products containing kratom, a substance with opioidlike effects, which are sold over the counter in many gas stations, claim to be herbal supplements but are mislabeled.
• Under a 1994 law, dietary supplements are classified as food, not as drugs.

The FDA is cracking down

• In August 2021, the FDA cracked down on some of these weight loss products because of the presence of undeclared drugs.
• While the FDA may take further action beyond the recalls, the agency acknowledged that it is not able to test every weight loss supplement for contamination with drugs.
• Some weight loss supplements may have FDA warnings on them.

Eating disorders

• People who have eating disorders often suffer related health issues such as bone loss, osteoporosis and vitamin deficiencies.
• Diet pill and supplement use has also been associated with increased risk for developing eating disorders and disordered eating, as well as low self-esteem, depression and substance use.
• While dietary supplements do not solely cause eating disorders or disordered eating, they are one contributing factor that may be addressed with preventive measures and regulations.

The allure of protein powders and fitness supplements

• Protein powders and other fitness supplements also have wide appeal.
• But a growing problem in boys is the use of fitness supplements such as protein powder and creatine products, a compound that supplies energy to the muscles.
• Protein powders make claims of building lean muscles, while creatine boasts providing energy for short-term, intense exercise.

Possible solutions

• One proposed regulation by researchers at Harvard University includes taxing dietary supplements whose labels tout weight loss benefits.
• Another policy recommendation involves banning the sale of dietary supplements and other weight loss products to protect minors from these underregulated and potentially dangerous products.

The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

• “The data to date validates our belief in ompenaclid as a potential first-in-class therapy for advanced colorectal cancer and underscores the power of our proprietary target discovery platform RNA-DRIVEr™.
• Furthermore, the parties agreed to collaborate on Inspirna’s SLC6A8 follow-on compounds for which Inspirna will retain US co-development and co-commercialization rights.
• Ompenaclid was well-tolerated, with no dose-limiting toxicities observed in the dose-escalation cohort and combination safety profile comparable to FOLFIRI plus bevacizumab backbone treatment.
• Inspirna has initiated a Phase 2 double-blind randomized controlled trial in 2L RAS mutant advanced or metastatic mCRC comparing ompenaclid versus placebo plus FOLFIRI and bevacizumab.